Puma Biotechnology
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology falls more than 20%
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2020 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology Profile | FDA Health News
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Profile | FDA Health News
